{"pmid":32426751,"pmcid":"PMC7188425","title":"The Clinical Presentation and Immunology of Viral Pneumonia and Implications for Management of Coronavirus Disease 2019.","text":["The Clinical Presentation and Immunology of Viral Pneumonia and Implications for Management of Coronavirus Disease 2019.","This review will briefly examine the clinical presentation and important immunology of viral pneumonia with a focus on severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019). Data Sources Study Selection Data Extraction and Data Synthesis: The most relevant, original and review literature were assessed for inclusion in this review. Sources included the Centers for Disease Control and Prevention, World Health Organization, and PubMed. Conclusions: Pneumonia is a leading cause of hospitalization and death worldwide, with viral etiologies being very common. Given the rapidly emerging pandemic associated with the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019, it is important to review the clinical presentation and immunologic changes associated with viral pneumonia. Symptoms of viral pneumonia include common respiratory tract infection symptoms of cough, fever, and shortness of breath. Immunologic changes include up-regulation of airway pro-inflammatory cytokines and pathogen- and damage-associated molecular patterns contributing to cytokine and genomic changes. Coronavirus disease 2019 clinical presentation is typical of viral pneumonia with an increased prevalence of early pulmonary infiltrates and lymphopenia. Principles of early coronavirus disease 2019 management and isolation as well as potential therapeutic approaches to the emerging pandemic are discussed.","Crit Care Explor","Darden, Dijoia B","Hawkins, Russell B","Larson, Shawn D","Iovine, Nicole M","Prough, Donald S","Efron, Philip A","32426751"],"abstract":["This review will briefly examine the clinical presentation and important immunology of viral pneumonia with a focus on severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019). Data Sources Study Selection Data Extraction and Data Synthesis: The most relevant, original and review literature were assessed for inclusion in this review. Sources included the Centers for Disease Control and Prevention, World Health Organization, and PubMed. Conclusions: Pneumonia is a leading cause of hospitalization and death worldwide, with viral etiologies being very common. Given the rapidly emerging pandemic associated with the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019, it is important to review the clinical presentation and immunologic changes associated with viral pneumonia. Symptoms of viral pneumonia include common respiratory tract infection symptoms of cough, fever, and shortness of breath. Immunologic changes include up-regulation of airway pro-inflammatory cytokines and pathogen- and damage-associated molecular patterns contributing to cytokine and genomic changes. Coronavirus disease 2019 clinical presentation is typical of viral pneumonia with an increased prevalence of early pulmonary infiltrates and lymphopenia. Principles of early coronavirus disease 2019 management and isolation as well as potential therapeutic approaches to the emerging pandemic are discussed."],"journal":"Crit Care Explor","authors":["Darden, Dijoia B","Hawkins, Russell B","Larson, Shawn D","Iovine, Nicole M","Prough, Donald S","Efron, Philip A"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426751","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/CCE.0000000000000109","keywords":["coronavirus","immunology","influenza virus","severe acute respiratory syndrome","viral pneumonia"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1667252837838487552,"score":9.490897,"similar":[{"pmid":32489027,"title":"[Recent advances in treatment of viral pneumonia using Chinese patent medicine].","text":["[Recent advances in treatment of viral pneumonia using Chinese patent medicine].","Viral pneumonia is caused by a spreading of lung infection caused by respiratory viruses. Some virus infections were found to be highly aggressive, leading to lung inflammation and severe damage in respiratory system with high fatality rate. Currently, there is no effective therapeutic drugs in the clinic. The common clinical symptoms of viral pneumonias include fever, rhinitis, runny nose, nonproductive cough, fatigue, myalgias and headaches after the immune system being tricked by driving cytokines and overactivated immune response induced by cytokine storms. Patients with severe symptoms could get persistent high fever, dysfunctional breathing, consciousness disorders and even respiratory failure, post-inflammatory pulmonary fibrosis, multi-organ damages, shock and so on. Most clinical treatments are used to inhibit virus replication, relieve symptoms, inhibit excessive inflammatory response, regulate immune balance and protect organs. Both applied and basic research demonstrate that Chinese patent medicine has certain anti-viral effects, effectively inhibiting viral pneumonia transiting from mild to severe, rapid relieving of patient symptoms because of their multi-component and multi-target integrated roles. This review has summarized the reports on the treatment of viral pneumonia. Based on the pathogenic characteristics of viral pneumonia, this paper summarizes the diverse roles of the marketed Chinese patent medicine, such as their effects in inhibiting the progress of viral replication and overactivated inflammatory response, regulating immune balance, attenuating pulmonary fibrosis and so forth. Our paper summarizes the advantages of Chinese patient medicine in the treatment of viral pneumonia, based on which improvements of clinical therapy are expected to be made soon.","Zhongguo Zhong Yao Za Zhi","Wang, Tao","Han, Li-Feng","Wang, Yue-Fei","Miao, Lin","Yang, Jian","Zhang, Jun-Hua","Gao, Xiu-Mei","Zhang, Bo-Li","32489027"],"abstract":["Viral pneumonia is caused by a spreading of lung infection caused by respiratory viruses. Some virus infections were found to be highly aggressive, leading to lung inflammation and severe damage in respiratory system with high fatality rate. Currently, there is no effective therapeutic drugs in the clinic. The common clinical symptoms of viral pneumonias include fever, rhinitis, runny nose, nonproductive cough, fatigue, myalgias and headaches after the immune system being tricked by driving cytokines and overactivated immune response induced by cytokine storms. Patients with severe symptoms could get persistent high fever, dysfunctional breathing, consciousness disorders and even respiratory failure, post-inflammatory pulmonary fibrosis, multi-organ damages, shock and so on. Most clinical treatments are used to inhibit virus replication, relieve symptoms, inhibit excessive inflammatory response, regulate immune balance and protect organs. Both applied and basic research demonstrate that Chinese patent medicine has certain anti-viral effects, effectively inhibiting viral pneumonia transiting from mild to severe, rapid relieving of patient symptoms because of their multi-component and multi-target integrated roles. This review has summarized the reports on the treatment of viral pneumonia. Based on the pathogenic characteristics of viral pneumonia, this paper summarizes the diverse roles of the marketed Chinese patent medicine, such as their effects in inhibiting the progress of viral replication and overactivated inflammatory response, regulating immune balance, attenuating pulmonary fibrosis and so forth. Our paper summarizes the advantages of Chinese patient medicine in the treatment of viral pneumonia, based on which improvements of clinical therapy are expected to be made soon."],"journal":"Zhongguo Zhong Yao Za Zhi","authors":["Wang, Tao","Han, Li-Feng","Wang, Yue-Fei","Miao, Lin","Yang, Jian","Zhang, Jun-Hua","Gao, Xiu-Mei","Zhang, Bo-Li"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489027","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.19540/j.cnki.cjcmm.20200312.502","keywords":["2019-ncov","covid-19","immunity","inflammation","pulmonary fibrosis","viral pneumonia","viral replication"],"locations":["Chinese","Chinese","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1668623433742680065,"score":198.74768},{"pmid":32426749,"pmcid":"PMC7188429","title":"Neurologic Manifestations of Severe Respiratory Viral Contagions.","text":["Neurologic Manifestations of Severe Respiratory Viral Contagions.","Endemic and pandemic viral respiratory infections have recently emerged as a critical topic of investigation given the recent severe acute respiratory syndrome coronavirus-2 outbreak. Data from such outbreaks indicate that severe systemic comorbidities including acute neurologic illness are associated with illness and lead to significant outcome differences. Herein, we will discuss the neurologic manifestations of severe viral respiratory infections including coronavirus, influenza, respiratory syncytial virus, metapneumovirus, and enterovirus. Data Sources: PubMed and EMBASE were searched by two independent investigators up to March 2020. Study Selection: Data selection included preclinical and clinical studies detailing neurologic manifestations of viral respiratory infections. Data Extraction and Synthesis: Two independent investigators reviewed and extracted the data. Conclusions: Neurologic manifestations including seizures, status epilepticus, encephalitis, critical illness neuromyopathy, acute disseminated encephalomyelitis, acute necrotizing encephalitis, Guillan-Barre syndrome, transverse myelitis, and acute flaccid myelitis have all been associated with severe viral respiratory infections. Having an understanding of the direct neurotropism of such viruses is imperative to understanding pathogenesis, clinical presentation, and potential treatment paradigms aimed at improving morbidity and mortality.","Crit Care Explor","Robinson, Christopher P","Busl, Katharina M","32426749"],"abstract":["Endemic and pandemic viral respiratory infections have recently emerged as a critical topic of investigation given the recent severe acute respiratory syndrome coronavirus-2 outbreak. Data from such outbreaks indicate that severe systemic comorbidities including acute neurologic illness are associated with illness and lead to significant outcome differences. Herein, we will discuss the neurologic manifestations of severe viral respiratory infections including coronavirus, influenza, respiratory syncytial virus, metapneumovirus, and enterovirus. Data Sources: PubMed and EMBASE were searched by two independent investigators up to March 2020. Study Selection: Data selection included preclinical and clinical studies detailing neurologic manifestations of viral respiratory infections. Data Extraction and Synthesis: Two independent investigators reviewed and extracted the data. Conclusions: Neurologic manifestations including seizures, status epilepticus, encephalitis, critical illness neuromyopathy, acute disseminated encephalomyelitis, acute necrotizing encephalitis, Guillan-Barre syndrome, transverse myelitis, and acute flaccid myelitis have all been associated with severe viral respiratory infections. Having an understanding of the direct neurotropism of such viruses is imperative to understanding pathogenesis, clinical presentation, and potential treatment paradigms aimed at improving morbidity and mortality."],"journal":"Crit Care Explor","authors":["Robinson, Christopher P","Busl, Katharina M"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426749","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1097/CCE.0000000000000107","keywords":["encephalitis","meningitis","neurology","respiratory","seizure","virus"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1667252838031425537,"score":185.19151},{"pmid":32217835,"pmcid":"PMC7190990","title":"Clinical and immunological features of severe and moderate coronavirus disease 2019.","text":["Clinical and immunological features of severe and moderate coronavirus disease 2019.","BACKGROUNDSince December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is now becoming a global threat. We aimed to delineate and compare the immunological features of severe and moderate COVID-19.METHODSIn this retrospective study, the clinical and immunological characteristics of 21 patients (17 male and 4 female) with COVID-19 were analyzed. These patients were classified as severe (11 cases) and moderate (10 cases) according to the guidelines released by the National Health Commission of China.RESULTSThe median age of severe and moderate cases was 61.0 and 52.0 years, respectively. Common clinical manifestations included fever, cough, and fatigue. Compared with moderate cases, severe cases more frequently had dyspnea, lymphopenia, and hypoalbuminemia, with higher levels of alanine aminotransferase, lactate dehydrogenase, C-reactive protein, ferritin, and D-dimer as well as markedly higher levels of IL-2R, IL-6, IL-10, and TNF-alpha. Absolute numbers of T lymphocytes, CD4+ T cells, and CD8+ T cells decreased in nearly all the patients, and were markedly lower in severe cases (294.0, 177.5, and 89.0 x 106/L, respectively) than moderate cases (640.5, 381.5, and 254.0 x 106/L, respectively). The expression of IFN-gamma by CD4+ T cells tended to be lower in severe cases (14.1%) than in moderate cases (22.8%).CONCLUSIONThe SARS-CoV-2 infection may affect primarily T lymphocytes, particularly CD4+ and CD8+ T cells, resulting in a decrease in numbers as well as IFN-gamma production by CD4+ T cells. These potential immunological markers may be of importance because of their correlation with disease severity in COVID-19.TRIAL REGISTRATIONThis is a retrospective observational study without a trial registration number.FUNDINGThis work is funded by grants from Tongji Hospital for the Pilot Scheme Project, and partly supported by the Chinese National Thirteenth Five Years Project in Science and Technology for Infectious Disease (2017ZX10202201).","J Clin Invest","Chen, Guang","Wu, Di","Guo, Wei","Cao, Yong","Huang, Da","Wang, Hongwu","Wang, Tao","Zhang, Xiaoyun","Chen, Huilong","Yu, Haijing","Zhang, Xiaoping","Zhang, Minxia","Wu, Shiji","Song, Jianxin","Chen, Tao","Han, Meifang","Li, Shusheng","Luo, Xiaoping","Zhao, Jianping","Ning, Qin","32217835"],"abstract":["BACKGROUNDSince December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is now becoming a global threat. We aimed to delineate and compare the immunological features of severe and moderate COVID-19.METHODSIn this retrospective study, the clinical and immunological characteristics of 21 patients (17 male and 4 female) with COVID-19 were analyzed. These patients were classified as severe (11 cases) and moderate (10 cases) according to the guidelines released by the National Health Commission of China.RESULTSThe median age of severe and moderate cases was 61.0 and 52.0 years, respectively. Common clinical manifestations included fever, cough, and fatigue. Compared with moderate cases, severe cases more frequently had dyspnea, lymphopenia, and hypoalbuminemia, with higher levels of alanine aminotransferase, lactate dehydrogenase, C-reactive protein, ferritin, and D-dimer as well as markedly higher levels of IL-2R, IL-6, IL-10, and TNF-alpha. Absolute numbers of T lymphocytes, CD4+ T cells, and CD8+ T cells decreased in nearly all the patients, and were markedly lower in severe cases (294.0, 177.5, and 89.0 x 106/L, respectively) than moderate cases (640.5, 381.5, and 254.0 x 106/L, respectively). The expression of IFN-gamma by CD4+ T cells tended to be lower in severe cases (14.1%) than in moderate cases (22.8%).CONCLUSIONThe SARS-CoV-2 infection may affect primarily T lymphocytes, particularly CD4+ and CD8+ T cells, resulting in a decrease in numbers as well as IFN-gamma production by CD4+ T cells. These potential immunological markers may be of importance because of their correlation with disease severity in COVID-19.TRIAL REGISTRATIONThis is a retrospective observational study without a trial registration number.FUNDINGThis work is funded by grants from Tongji Hospital for the Pilot Scheme Project, and partly supported by the Chinese National Thirteenth Five Years Project in Science and Technology for Infectious Disease (2017ZX10202201)."],"journal":"J Clin Invest","authors":["Chen, Guang","Wu, Di","Guo, Wei","Cao, Yong","Huang, Da","Wang, Hongwu","Wang, Tao","Zhang, Xiaoyun","Chen, Huilong","Yu, Haijing","Zhang, Xiaoping","Zhang, Minxia","Wu, Shiji","Song, Jianxin","Chen, Tao","Han, Meifang","Li, Shusheng","Luo, Xiaoping","Zhao, Jianping","Ning, Qin"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32217835","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1172/JCI137244","keywords":["covid-19","cytokines","immunology","infectious disease","respiration","t cells"],"locations":["Wuhan","ferritin"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism"],"weight":1,"_version_":1666138490489798656,"score":182.93904},{"pmid":32498762,"title":"Coronavirus Disease 2019: Clinical Review.","text":["Coronavirus Disease 2019: Clinical Review.","INTRODUCTION: In December 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in Wuhan, the capital of Central China's Hubei Province and has been declared a public health emergency of international concern by the World Health Organization since January 2020. MATERIAL AND METHODS: A comprehensive search using the PubMed database was carried out to summarize the latest published information about the epidemiology, definition, pathogenesis, clinical characteristics, treatment options, prognosis and prevention of coronavirus disease 2019. DISCUSSION: This new strain of coronavirus, named severe acute respiratory syndrome coronavirus 2, enters human cells that express angiotensin-converting enzyme II receptors, which exist in the respiratory, gastrointestinal and genitourinary tracts and heart, causing coronavirus disease. Transmission occurs essentially through the respiratory tract and the main symptoms are fever, cough and dyspnea. Diagnosis is based on epidemiological, clinical and imaging features and confirmed by nucleic acid testing. CONCLUSION: Despite intensive research, the exact origin of the virus and pathophysiology of coronavirus disease is not yet completely known, and clinically approved vaccines and drugs that target severe acute respiratory syndrome coronavirus 2 are lacking.","Acta Med Port","Gouveia, Cristina Carvalho","Campos, Luis","32498762"],"abstract":["INTRODUCTION: In December 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in Wuhan, the capital of Central China's Hubei Province and has been declared a public health emergency of international concern by the World Health Organization since January 2020. MATERIAL AND METHODS: A comprehensive search using the PubMed database was carried out to summarize the latest published information about the epidemiology, definition, pathogenesis, clinical characteristics, treatment options, prognosis and prevention of coronavirus disease 2019. DISCUSSION: This new strain of coronavirus, named severe acute respiratory syndrome coronavirus 2, enters human cells that express angiotensin-converting enzyme II receptors, which exist in the respiratory, gastrointestinal and genitourinary tracts and heart, causing coronavirus disease. Transmission occurs essentially through the respiratory tract and the main symptoms are fever, cough and dyspnea. Diagnosis is based on epidemiological, clinical and imaging features and confirmed by nucleic acid testing. CONCLUSION: Despite intensive research, the exact origin of the virus and pathophysiology of coronavirus disease is not yet completely known, and clinically approved vaccines and drugs that target severe acute respiratory syndrome coronavirus 2 are lacking."],"journal":"Acta Med Port","authors":["Gouveia, Cristina Carvalho","Campos, Luis"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498762","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.20344/amp.13957","keywords":["covid-19","coronavirus infections","severe acute respiratory syndrome"],"locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668804508822536193,"score":167.6112},{"pmid":31944312,"pmcid":"PMC7166954","title":"Recent advances in the detection of respiratory virus infection in humans.","text":["Recent advances in the detection of respiratory virus infection in humans.","Respiratory tract viral infection caused by viruses or bacteria is one of the most common diseases in human worldwide, while those caused by emerging viruses, such as the novel coronavirus, 2019-nCoV that caused the pneumonia outbreak in Wuhan, China most recently, have posed great threats to global public health. Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics. Conventional diagnostic tests, such as the assays for rapid detection of antiviral antibodies or viral antigens, are widely used in many clinical laboratories. With the development of modern technologies, new diagnostic strategies, including multiplex nucleic acid amplification and microarray-based assays, are emerging. This review summarizes currently available and novel emerging diagnostic methods for the detection of common respiratory viruses, such as influenza virus, human respiratory syncytial virus, coronavirus, human adenovirus, and human rhinovirus. Multiplex assays for simultaneous detection of multiple respiratory viruses are also described. It is anticipated that such data will assist researchers and clinicians to develop appropriate diagnostic strategies for timely and effective detection of respiratory virus infections.","J Med Virol","Zhang, Naru","Wang, Lili","Deng, Xiaoqian","Liang, Ruiying","Su, Meng","He, Chen","Hu, Lanfang","Su, Yudan","Ren, Jing","Yu, Fei","Du, Lanying","Jiang, Shibo","31944312"],"abstract":["Respiratory tract viral infection caused by viruses or bacteria is one of the most common diseases in human worldwide, while those caused by emerging viruses, such as the novel coronavirus, 2019-nCoV that caused the pneumonia outbreak in Wuhan, China most recently, have posed great threats to global public health. Identification of the causative viral pathogens of respiratory tract viral infections is important to select an appropriate treatment, save people's lives, stop the epidemics, and avoid unnecessary use of antibiotics. Conventional diagnostic tests, such as the assays for rapid detection of antiviral antibodies or viral antigens, are widely used in many clinical laboratories. With the development of modern technologies, new diagnostic strategies, including multiplex nucleic acid amplification and microarray-based assays, are emerging. This review summarizes currently available and novel emerging diagnostic methods for the detection of common respiratory viruses, such as influenza virus, human respiratory syncytial virus, coronavirus, human adenovirus, and human rhinovirus. Multiplex assays for simultaneous detection of multiple respiratory viruses are also described. It is anticipated that such data will assist researchers and clinicians to develop appropriate diagnostic strategies for timely and effective detection of respiratory virus infections."],"journal":"J Med Virol","authors":["Zhang, Naru","Wang, Lili","Deng, Xiaoqian","Liang, Ruiying","Su, Meng","He, Chen","Hu, Lanfang","Su, Yudan","Ren, Jing","Yu, Fei","Du, Lanying","Jiang, Shibo"],"date":"2020-01-17T11:00:00Z","year":2020,"_id":"31944312","source":"PubMed","week":"20203|Jan 13 - Jan 19","doi":"10.1002/jmv.25674","keywords":["adenovirus","coronavirus","diagnostic methods","influenza virus","respiratory syncytial virus","respiratory viral infection","rhinovirus"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493078732800,"score":167.38922}]}